Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The fibrotic tumor stroma
Mitsuo Yamauchi, … , Don L. Gibbons, Jonathan M. Kurie
Mitsuo Yamauchi, … , Don L. Gibbons, Jonathan M. Kurie
Published January 2, 2018
Citation Information: J Clin Invest. 2018;128(1):16-25. https://doi.org/10.1172/JCI93554.
View: Text | PDF
Review Series Article has an altmetric score of 4

The fibrotic tumor stroma

  • Text
  • PDF
Abstract

Intratumoral fibrosis results from the deposition of a cross-linked collagen matrix by cancer-associated fibroblasts (CAFs). This type of fibrosis has been shown to exert mechanical forces and create a biochemical milieu that, together, shape intratumoral immunity and influence tumor cell metastatic behavior. In this Review, we present recent evidence that CAFs and tumor cells are regulated by provisional matrix molecules, that metastasis results from a change in the type of stromal collagen cross-link, and that fibrosis and inflammation perpetuate each other through proteolytic and chemotactic mediators released into the tumor stroma. We also discuss aspects of the emerging biology that have potential therapeutic value.

Authors

Mitsuo Yamauchi, Thomas H. Barker, Don L. Gibbons, Jonathan M. Kurie

×

Figure 2

Collagen cross-linking in fibrosis and cancer.

Options: View larger image (or click on image) Download as PowerPoint
Collagen cross-linking in fibrosis and cancer.
(A) Transmission electron...
(A) Transmission electron microscopic image of tumor tissue showing dense type I collagen fibrils (reprinted with permission from the Journal of Biological Chemistry, ref. 126). Rectangle indicates a single fibril. Below, a sketch represents type I collagen molecules (wavy lines) packed in a fibril in parallel and staggered with respect to one another by approximately 67 nm. (B) Cross-linking sites of adjacent collagen molecules. Initial cross-links are indicated by dashed lines. Two telopeptidyl lysine aldehydes (O=CH) can cross-link within the same molecule (intramolecular cross-link). Telopeptidyl lysine- and hydroxylysine-aldehyde (O=CH) can condense with ε-amino groups (NH2) of juxtaposed helical lysine or hydroxylysine residues to form intermolecular cross-links. Helical cross-linking hydroxylysine residues near the N-terminus are one of the major glycosylation sites (galactose or galactose-glucose indicated in tan) in type I collagen, contributing to glycosylated cross-linking. (C) Major cross-linking pathways characterized in fibrotic and cancer tissues (for comprehensive cross-linking pathways, see ref. 65). Lysyl oxidases (LOXs) initiate cross-linking by converting lysine or hydroxylysine residues in the telopeptides to aldehyde (t-Lysald and t-Hylald, respectively). Then the aldehyde condenses with another t-Lysald in the same molecule or juxtaposed helical Lys (h-Lys) or Hyl (h-Hyl) on a neighboring molecule. These divalent cross-links can then mature into tri- and tetravalent cross-links. All cross-links are intermolecular cross-links except an aldol condensation product (ACP). In fibrosis and cancer, the pathway is driven toward LH2-mediated Hylald-derived pathway, as indicated by blue boxes (115). d, deoxy; deH, dehydro; DHLNL, dihydroxylysinonorleucine; h, helical; HHMD, histidinohydroxymerodesmosine; HLNL, hydroxylysinonorleucine; LH2, lysyl hydroxylase-2; Pyr, pyridinoline; t, telopeptidyl.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 7 X users
On 1 Facebook pages
256 readers on Mendeley
See more details